Viatris is recalling 9,515 bottles of Lyrica CR (pregabalin) 330 mg extended-release tablets because the medication failed to meet dissolution specifications. This means the tablets may not release the active ingredient into the body as intended. The affected product is sold in 30-count bottles and was distributed nationwide in the United States by the Parke-Davis Division of Pfizer.
When a drug fails dissolution tests, it may release the medication too slowly or too quickly. This can lead to unpredictable levels of the medication in the bloodstream, potentially making the treatment for nerve pain or seizures less effective.
Return to pharmacy and consult healthcare provider.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.